There were more than 20 doses of Dapagliflozin 5mg

but cascading was not applied?

Because 21 products are listed for the first time

Forxiga 5mg, it was withdrawn from the domestic market

Even though there are 21 SGLT-2 series Dapagliflozin propanediol hydrate 5mg products listed for reimbursement, the stepped drug price was not applied to the newly listed items in November.

 

Why?

 

This is because all 21 products were viewed as first-time registered products.

 

According to the industry on the 1st, Nexpharm Korea's 'Floga 5mg' met the standard requirements when it was listed for reimbursement in November, and was added to the 59.5% given to first generics to the existing highest price of the same drug, setting a price of 291 won per tablet.

 

Even though there are already 21 generics on the benefit list, they were calculated using the highest price formula.

 

The stepped drug price system implemented in 2020 is such that when generics enter the market with more than 20 already listed identical products, the price is capped at 85% of the lowest price for the same drug or 38.69%.

 

However, this time, the stepped drug price was not applied.

 

This is because, in the case of a first-registered product, multiple products are considered one.

 

Dapagliflozin 5mg was listed for the first time in Korea on April 8.

 

AstraZeneca's original drug, Forxiga 5mg, was listed on the reimbursement list in 2014 but was deleted in 2018, so there was no identical drug on the reimbursement list at the time of listing the generics.

 

Therefore, all 21 products listed for reimbursement on April 8 were recognized as first-listed.

 

However, for the same drug that will be registered in the future, a stepped drug price will be applied.

 

From now on, drug prices will be calculated based on the total number of registered items, including the first listed products.

 

Therefore, the next item listed for benefit is calculated at 85% of the lower of the lowest price for the same product or 38.69%, regardless of whether the standard requirements are met.

 

Nexpharm Korea's Floga 5mg was listed for reimbursement 7 months later than competing drugs, but was fortunate enough to receive a high price.

 

An industry official said, "The generic calculation standards themselves were complicated, so in the case of Dapagliflozin 5mg, it was not possible to know whether the stepped drug price would be applied in the field." He explained, “It was only later that I understood why Nexpharm products received the highest price plus extra.”